Rachel has extensive experience in biotech. •Pharmaceutical executive with extensive experience in Product Development from pre-IND to Phase IV/compound commercialization of small molecules, cytotoxics and biologics in oncology and immuno-oncology. •Proven success in supervising Product Development strategy and tactics over ~18 years in 4 large pharmaceutical companies and in small biotech and with supervision of the successful development of 2 new molecular entities in oncology (NEXAVAR and YERVOY). •As Senior Vice President and Head of Immuno-Oncology at AstraZeneca, successfully and swiftly (within 9 months) built a high-performing late-stage Immuno-Oncology department and supervised the initiation of the late stage global development of tremelimumab, MEDI4736 (PD-L1 inhibitor) and the treme/MEDI4736 combination. •In the roles of Executive Vice President, Chief Medical Officer (Mirati Therapeutics, formerly MethylGene Inc.) and/or VP, Global Development (BMS) successfully managed all aspects of specific asset development including clinical, statistics, operations, regulatory, manufacturing, medical, publications, pre-launch and post-launch activities with a focus on global and regional development, including Asia and Japan. •Extensive experience interacting internally with finance and research functions, and externally with investors, analysts, scientific leaders and large and small pharma collaborators. •Extensive experience in-licensing compounds and interfacing, through Alliances, between large and small biotech companies. •Broad interaction with global regulatory authorities including supervision of IND and NDA documents, ODAC preparation and label negotiations. •Led improvement of process projects in global development and medical affairs. •Participated on the leadership team and facilitated exit management following the BMS acquisition of 7Medarex and transition of Mirati Therapeutics from Canada to the US. CytomX is a clinical-stage biopharmaceutical company with a unique approach to treating cancer. After their IPO, they have a market cap of nearly $1B.
June 28 – 29, 2018
10:00 PM – 1:00 AM UTC
| 10:00 PM | Networking and Food |
| 11:00 PM | Fireside Chat |
| 12:00 AM | Networking |
This is Startup Grind. We are the world’s largest startup community.
Our Mission
To give startups everywhere the education and opportunities they need to build, grow, and scale their companies.
Our Values
We believe in making friends, not contacts. We believe in giving first, not taking. We believe in helping others before helping yourself.
Tools & Discounts for Startups
Take advantage of resources and offers provided by organizations we know and love, designed to help you navigate the startup journey.
Global Conference
Our annual flagship event in Silicon Valley brings together thousands of startup teams, investors and organizations from all over the world.
Join the Startup Membership
This membership gives you free access to networking, events, mentorship, office hours, and other exclusive opportunities curated by Startup Grind HQ.
